Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Arthur et al
Kim T, Park N, Jo B, Lee BS, Keem M, Kwon T, et al
The primary aim was to evaluate the efficacy and safety of semaglutide compared with other anti-diabetic therapies in patients with T2DM as second-line in patients treated with metformin and as third-line in patients with metformin and SU
Retatrutide is an investigational once-weekly subcutaneous triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly
US$ 21.60
US$ 26.67
US$ 21.79
US$ 27.13
,aspect=ignore)
,aspect=ignore)
US$ 24.61
US$ 26.56
